Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Patent
1996-05-17
1997-06-17
Fleisher, Mindy
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
435 74, 435 78, 435 23, 435219, 435963, 530324, 530326, 530332, 530351, C12Q 137, C07K 702, C07K 1481
Patent
active
056395930
ABSTRACT:
Compositions and methods are described for identifying inhibitors of mature protein hormone formation from a prohormone, and prophylactic and therapeutic uses of the inhibitors for treating diseases associated with elevated levels of the mature hormones, particulary sepsis, AIDS and autoimmune diseases.
REFERENCES:
patent: 4190496 (1980-02-01), Rubenstein et al.
patent: 4323647 (1982-04-01), Monji et al.
patent: 4677063 (1987-06-01), Mark et al.
patent: 4766069 (1988-08-01), Auron et al.
patent: 4808611 (1989-02-01), Cosman
patent: 4859600 (1989-08-01), Gray et al.
patent: 4892813 (1990-01-01), Cohen et al.
patent: 4897444 (1990-01-01), Brynes et al.
patent: 4923802 (1990-05-01), Gallis
patent: 5138035 (1992-08-01), Wakselman et al.
patent: 5231105 (1993-07-01), Shoji et al.
patent: 5242904 (1993-09-01), Kettner et al.
patent: 5250681 (1993-10-01), Shoji et al.
patent: 5288612 (1994-02-01), Griffin et al.
patent: 5422425 (1995-06-01), Kriegler et al.
patent: 5545518 (1996-08-01), Kriegler
Cseh et al. "Alternative Cleavage of the Cachectin/TNF Propeptide Results in a Larger Inactive Form of Secreted Protein" JBL 264 16256-16260 1989.
Tracey et al., "Ant-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia," Nature, 330:662-664 (Dec. 17, 1987).
Decker et al., "Cell-Associated Tumour Necrosis Factor (TNF) as a Killing Mechanism of Activated Cytotoxic Macrophages," J. Immunol., 138:957-962 (Feb. 1, 1987).
Kriegler et al., "A Novel Form of TNF/Cachetin Is a Cell Surface Cytotoxic Transmembrane Protein: Ramifications for the Complex Physiology of TNF," Cell, 53:45-53 (Apr. 8, 1988).
Folks et al., "Tumour necrosis factor .alpha. induces expression of human immunodeficiency virus in a chronically infected T-cell clone," PNAS (USA), 86:2365-2368 (Apr. 1989).
Elliot, et al., "Treatment of Rheumatoid Arthritis With Chimeric Antibodies to tumour Necrosis Factor .alpha.," Arthritis & Rheumatism, 36:1681-1690 (Dec. 1993).
Seckinger et al., "A Human Inhibitor of Tumour Necrosis Factor .alpha.," J. Exp. Med.. 167:1511-1516 (1988).
Seckinger et al., "Purification and Biologic Characterization of a Specific Tumour Necrosis Factor .alpha. Inhibitor," J. Biol. Chem., 264:11966-11973 (1989).
Dinarello et al., "Multiple biological Activities of Human Recombinant Interleukin-1," J. Clin. Invest. 77:1734-1739 (1986).
Arend et al., "Effects of Immune Compleses on Production by Human Monocytes of Interleukin-1 or an Interleukin-1 Inhibitor," J. Immunol., 134:3868-3975 (1985).
Seckinger et al., "A Urine Inhibitor of Interleukin-1 Activity that Blocks Ligand Binding," J. Immunol., 139:1546-1549 (1987).
Hannum et al., "Interleukin-1 Receptor Antagonist Activity of a Human Interleukin-1 Inhibitor," Nature, 343:336-340 (1990).
Eisenberg et al., "Primary Structure and Expression from Complementary DNA of a Human Interleukin-1 Receptor Antagonist," Nature, 343:341-346 (1990).
Kostura et al., "Identification of a monocyte specifc pre-interleukin 1.beta. convertase activity," PNAS (USA), 86:5227-5231 (Jul. 1989).
Scott et al., "Immunogenicity of Biotinylated Hapten-Avidin Complexes," Molecular Immunology, 21:1055-1060 (1984).
Tsuchiya et al., "Establishment and Characterization of a Human Acute Monocytic Leukemia Cell Line (THP-1)," Int. J. Cancer, 26:171-176 (1980).
Krakauer & Oppenheim, "Interleukin 1 Production by a Human Acute Monocytic Leukemia Cell Line," Cell. Immunol., 80:223-229 (1983).
Silman & Katchalski, "Water-Insoluable Derivatives of Enzymes Antigens and Antibodies," Ann. Rev. Biochem., 35:873-908 (1966).
Shadle et al., "Human Macrophage Colony-Stimulating Factor Heterogeneity Results From Alternative mRNA Splicing, Differential Glycosylation, and Proteolytic processing," J. Cell. Biochem., 40:91-107 (1989).
Cseh et al., "Alternative Cleaveage of the Cachectin/TNF Propetide Results in a Larger, Inactive Form of Secreted Protein," J. Biol. Chem., 264:16256-16260 (1989).
Merrifield, "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide," J. Amer. Chem. Soc., 85:2149-2154 (Jul. 20, 1963).
Webb, "Arthritis Wonder Cure Wins Cautious Welcome," New Scientist, p. 16, (Feb. 12, 1994).
Elliott et al., "Treatment of Rheumatoid Arthritis with Chimeric Monoclonal Antibodies to Tumour Necrosis Factor .alpha.," Arthritis & Rheumatism, 36:1681-1690 (Dec. 1993).
Merrifield, "Solid Phase Synthesis," Science 232:341-347 (Apr. 18. 1986).
Beutler et al., "Passive Immunization Against Cachectin/Tumour Necrosis Factor Protects Mice from Lethal Effect of Endotoxin," Science, 229:869-871 (Aug. 30 ,1985).
Ohlsson et al., "Interleukin-1 receptor antagonist reduces mortality from endotoxin shock," Nature, 348:550-552 (Dec. 6, 1990).
Pickup et al., "Suppression of Inflammatory Responses to Viral Infection: Viral Inhibition of the IL-1.beta. Convertase," J. Cell. Biochem., vol. 16, Supp. B, p. 285, Abstr. J217 (1992).
Sleath et l., "Substrate Specificity of the Protease That Processes Human Interleukin-1.beta.," J. Biol. Chem., 265:14526-14528 (Aug. 25, 1990).
Kobayashi et al., "Human Pre-interleukin 1.alpha.and .beta.: Structural Features Revealed by Limited Proteolysis," Chem. Pharm. Bull., 39:1513-1517 (Jun., 1991).
Kriegler Michael
Nitecki Danute E.
Blackburn Robert P.
Cetus Oncology Corporation
Degen Nancy J.
Fleisher Mindy
Pochopien Donald J.
LandOfFree
Method for determining TNF does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for determining TNF, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for determining TNF will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2156895